Mol Interv. 2002 Oct;2(6):363-75, 339.

Apolipoprotein E, amyloid, and Alzheimer disease.

Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM.

Source

Neuroscience Discovery Research, Lilly Research Laboratories Indianapolis, IN 46285, USA.

Abstract

Despite important inroads into the molecular pathology of Alzheimer disease, effective long-term treatment for the condition remains elusive. Among the many gene products that are recognized as factors in the disease is apolipoprotein ( (apoE). The risk that specific isoforms of apoE pose with regard to Alzheimer Disease clearly varies, and so the roles that apoE plays in the brain will be crucial to a full understanding of the disease and to efforts to develop effective therapies.

PMID:: 14993413; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Medical

Supplemental Content

Save items

Related citations in PubMed

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. [J Biol Chem. 2005]
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease.
Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. J Biol Chem. 2005 Dec 30; 280(52):43236-42. Epub 2005 Oct 5.
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. [Neurobiol Dis. 2005]
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.
Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Stine WB, Manelli A, Sullivan P, Pasternak JF, LaDu MJ. Neurobiol Dis. 2005 Feb; 18(1):75-82.
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. [Neurobiol Aging. 2004]
Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation.
Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, et al. Neurobiol Aging. 2004 Oct; 25(9):1153-67.
Review Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. [J Neuropathol Exp Neurol. 2008]
Review Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE, Johanson CE. J Neuropathol Exp Neurol. 2008 Apr; 67(4):261-70.
Review Cholesterol and apoe: a target for Alzheimer's disease therapeutics. [Curr Drug Targets CNS Neurol D...]
Review Cholesterol and apoe: a target for Alzheimer's disease therapeutics.
Fenili D, McLaurin J. Curr Drug Targets CNS Neurol Disord. 2005 Oct; 4(5):553-67.

See reviews... See all...

Cited by 17 PubMed Central articles

Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain. [PLoS One. 2011]
Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-β in human Alzheimer brain.
Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, Hashimoto T, von Armin CA, Mielke M, Bacskai BJ, Hyman BT. PLoS One. 2011 Jan 31; 6(1):e14586. Epub 2011 Jan 31.
Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. [J Biol Chem. 2010]
Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion.
Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lütjohann D, Wunderlich P, et al. J Biol Chem. 2010 Nov 26; 285(48):37405-14. Epub 2010 Sep 28.
Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration. [Front Aging Neurosci. 2010]
Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration.
Ang ET, Tai YK, Lo SQ, Seet R, Soong TW. Front Aging Neurosci. 2010 Jul 21; 2. Epub 2010 Jul 21.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Apolipoprotein E, amyloid, and Alzheimer disease.
Apolipoprotein E, amyloid, and Alzheimer disease.
Mol Interv. 2002 Oct ;2(6):363-75, 339.

PubMed
NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elic...
NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope.
J Exp Med. 2004 Mar 1 ;199(5):629-40.

PubMed
Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its func...
Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding.
J Biol Chem. 2004 May 7 ;279(19):19691-7. Epub 2004 Mar 1 .

PubMed
Eprex warning issued, but no ban.
Eprex warning issued, but no ban.
CMAJ. 2004 Mar 2 ;170(5):778.

PubMed
Heart failure and the risk of shocks in patients with implantable cardioverter d...
Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
Circulation. 2004 Mar 23 ;109(11):1386-91. Epub 2004 Mar 1 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: